Director/PDMR Shareholding
Futura Medical plc announced that its Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares at 1 pence per share, totaling £60,000, as part of a fundraise. Specifically, Alex Duggan subscribed for 5,000,000 shares, Angela Hildreth for 500,000 shares, and Ken James for 500,000 shares. These transactions, which occurred on December 4, 2025, represent a direct investment by key management personnel into the company, potentially signaling confidence in its future prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, confirms that the following Directors and persons closely associated subscribed for an aggregate of 6,000,000 Ordinary Shares in the Company pursuant to the Fundraise announced on 13 November 2025.
Details are as below:
| Director | Number of New Shares | Issue Price per Ordinary Share | Total number of Ordinary Shares held following Admission | Percentage of Enlarged Share Capital |
|---|---|---|---|---|
| Alex Duggan* | 5,000,000 | 1 pence | 5,000,000 | 0.86% |
| Angela Hildreth | 500,000 | 1 pence | 642,857 | 0.11% |
| Ken James | 500,000 | 1 pence | 799,501 | 0.14% |
Further disclosures are contained in the tables below.
- Alex Duggan's shares were purchased by a wholly owned entity, Appia Healthcare Limited.
Capitalised terms not defined in this announced have the meanings given to them in the Fundraise Announcement dated 13 November 2025.
| a) | Name | Alex Duggan |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Subscription for ordinary shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 1p 5,000,000 |
| d) | Aggregated information - Aggregated volume - Price | 1. 5,000,000 1. £50,000 |
| e) | Date of the transaction | 4 December 2025 |
| f) | Place of the transaction | 1. Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Ken James |
| 2 | Reason for the notification | |
| a) | Position/status | Executive Director and Head of R&D |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Subscription for ordinary shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 1p 500,000 |
| d) | Aggregated information - Aggregated volume - Price | 1. 500,000 1. £5,000 |
| e) | Date of the transaction | 4 December 2025 |
| f) | Place of the transaction | 1. Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Angela Hildreth |
| 2 | Reason for the notification | |
| a) | Position/status | FD/COO |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Futura Medical plc |
| b) | LEI | 21380053QLT46UNV2303 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares at 0.2p each GB0033278473 |
| b) | Nature of the transaction | Subscription for ordinary shares |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 1. 1p 500,000 |
| d) | Aggregated information - Aggregated volume - Price | 1. 500,000 1. £5,000 |
| e) | Date of the transaction | 4 December 2025 |
| f) | Place of the transaction | 1. Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.